Research Article| Volume 17, ISSUE 3, P211-219, November 1993

Download started.


Effects of nandrolone decanoate on bone mass in established osteoporosis

      This paper is only available as a PDF. To read, Please Download here.


      A double-blind, randomized, placebo-controlled study was conducted in 46 postmenopausal women with established osteoporosis in order to assess the long-term effects of nandrolone decanoate on the bone mineral density (BMD) of the lumbar vertebrae and of the distal third of the radius and on the biochemical markers of bone turnover. The patients received intramuscular injections of placebo or 50 mg nandrolone decanoate every 3 weeks for 18 months. Thirty-two of the initial 46 patients completed 1 year of study and 25 completed the whole study period of 18 months. Overall, vertebral BMD increased by 2.9% in the nandrolone decanoate group and fell by 2.3% in the placebo group. Radial BMD showed a slight but transient improvement, with a subsequent return to basal levels in the nandrolone decanoate group, whereas there was a progressive decrease in the placebo group. Patients treated with nandrolone decanoate also complained less of bone pain. Urinary hydroxyproline decreased significantly in treated patients, whereas osteocalcin tended to increase, but the change was not significant. HDL cholesterol concentrations decreased only slightly and haemoglobin increased significantly in the nandrolone decanoate group. Two patients treated with nandrolone decanoate withdrew from the study because of hirsutism and hoarseness. The results indicate that nandrolone decanoate exerts positive effects on vertebral BMD and on bone pain in patients with established postmenopausal osteoporosis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cummings SR
        • Kelsey JL
        • Nevitt MC
        • O'Dowd KJ
        Epidemiology of osteoporosis and osteoporotic fractures.
        Epidemiol Rev. 1985; 7: 178-208
        • Gennari C
        Epidemiology and financial aspects of osteoporosis.
        in: Calcium regulation and bone metabolism: basic and clinical aspects. 9. 1986: 897-899
        • Recker RR
        Continuous treatment of osteoporosis: current status.
        Orthop Clin N Am. 1981; 12: 611-627
        • Albright F
        • Smith PH
        • Richardson AM
        Postmenopausal osteoporosis: its clinical features.
        J Am Med Assoc. 1941; 116: 2465-2474
        • Reifenstein EC
        • Albright F
        The metabolic effects of steroid hormones in osteoporosis.
        J Clin Invest. 1947; 26: 24-56
        • Kopera H
        The history of anabolic steroids and a review of clinical experience with anabolic steroids.
        Acta Endocrinol. 1985; 110: 11-18
        • Chesnut III, CH
        • Nelp WB
        • Baylink DJ
        • Denney JD
        Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass.
        Metabolism. 1977; 26: 267-277
        • Chesnut III, CH
        • Ivey JL
        • Gruber HE
        • Matthews M
        • Nelp WB
        • Sisom K
        • Baylink DJ
        Stanazolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action.
        Metabolism. 1983; 32: 571-580
        • Geusens P
        • Dequeker J
        Long-term effect of nandrolone decanoate, 1α-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
        Bone Miner. 1986; I: 347-357
        • Need AG
        • Horowitz M
        • Morris HA
        • Walker CJ
        • Nordin BEC
        Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
        Clin Orthop Rel Res. 1987; 225: 273-278
        • Need AG
        • Morris HA
        • Hartley TF
        • Horowitz M
        • Nordin BEC
        Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
        Calcif Tissue Int. 1987; 41: 7-10
        • Need AG
        • Horowitz M
        • Bridges A
        • Morris HA
        • Nordin BEC
        Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.
        Arch Intern Med. 1989; 149: 57-60
        • Gennari C
        • Agnusdei D
        • Gonnelli S
        • Nardi P
        Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established postmenopausal osteoporosis: a double-blind placebo controlled study.
        Maturitas. 1989; 11: 187-197
        • Johansen JS
        • Hassager C
        • Podenphant J
        • Riis BJ
        • Hartwell D
        • Thomsen K
        • Christiansen C
        Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?.
        Bone Miner. 1989; 6: 77-86
        • Leroy EC
        The technique and significance of hydroxyproline measurement in man.
        Adv Clin Chem. 1967; 10: 210-253
        • Beresford JN
        • Gallagher JA
        • Poser J
        • Gowen M
        • Couch M
        • Yates AJP
        • Kanis JA
        • Russell RGG
        Effects of the anabolic steroid, stanazolol, on human bone cells in vitro.
        in: XVII European Symposium on Calcified Tissues. Abs. 97. 1983
        • Taggart H.Mc A
        • Applebaum-Bowden D
        • Haffner S
        • Warnick GR
        • Cheung MC
        • Albers JJ
        • Chesnut III, CH
        • Hazzard WR
        Reduction in high density lipoproteins by anabolic steroid (Stanazolol) therapy for postmenopausal osteoporosis.
        Metabolism. 1982; 31: 1147-1152